Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, J. Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis P. Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert I. Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Manish Monga, Mark Lynch, William J. Geese, Justin Kopit, James W. Shaw, Maura L. Gillison

New England Journal of Medicine, 2016

University of Pittsburgh Medical Center, Institut Gustave Roussy, Cancer Institute (WIA), The University of Texas MD Anderson Cancer Center, Centre Léon Bérard, Centre Antoine Lacassagne, Cancer Prevention Institute of California, Stanford Cancer Institute, Fondazione IRCCS Istituto Nazionale dei Tumori, National Institute for Health Research, NIHR Biomedical Research Centre at The Royal Marsden and the ICR, Essen University Hospital, University of Chicago, University of Michigan–Ann Arbor, Emory University, Hospital Universitario 12 De Octubre, Dana-Farber Cancer Institute, University Hospital of Zurich, Kobe University Hospital, National Cancer Center Hospital East, Bristol-Myers Squibb (United States), The Ohio State University

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

4989

Citations

View on Google Scholar

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Abstract

Journal Details

Join JournalsHub

Welcome Back